SGLT-2 Inhibitors Cut Risk Of Death In Diabetics, Data Shows | Latest News RSS feed

SGLT-2 Inhibitors Cut Risk Of Death In Diabetics, Data Shows - Latest News


SGLT-2 inhibitors cut risk of death in diabetics, data shows

AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 ... read more

Real-world study shows type 2 diabetics treated with SGLT-2 inhibitors experienced less risk of hospitalization for heart failure and death

The data showed that treatment with SGLT-2 inhibitors ... and death from any cause by 51% (hazard ratio = 0.49; p<0.001). For the composite endpoint of hospitalization for heart failure and all-cause ... read more

AZ backs diabetes drug Farxiga with new cardio analysis

These include Eli Lilly/Boehringer Ingelheim’s Jardiance (empagliflozin), a rival from the SGLT-2 inhibitor class and the first diabetes drug to show a cardioprotective effect in high-risk patients. read more

Looking for another news?


Newer type 2 diabetes drugs show heart protective quality in study

WASHINGTON (Reuters) - A newer class of type 2 diabetes drugs significantly cut the risk of death and ... according to data released on Sunday from a so-called real world study sponsored by ... read more


Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

ANAHEIM, CA—Sodium-glucose co-transporter 2 (SGLT-2) inhibitors ... TCTMD that PAD is one of the most common complications of type 2 diabetes and that patients with suffer from both diseases at once ... read more

Daily aspirin to prevent heart attacks no longer recommended for older adults

If additional medications are needed, two new classes of medications are showing promise in reducing cardiovascular events in those with Type 2 diabetes: SGLT-2 inhibitors ... shows that they can also ... read more

Astrazeneca global study reveals diabetes medication significantly cuts death rates

Astrazeneca has hailed the success of its new Type 2 diabetes drugs, after a study of more than 300,000 people revealed it significantly cut the risk of death or heart failure ... whether the ... read more

AstraZeneca’s CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations for Heart Failure and Death versus Other Type-2 Diabetes Medicines

--(BUSINESS WIRE)--AstraZeneca today announced results of the first large real-world evidence study of its kind evaluating the risk of hospitalization for heart failure and death ... diabetes ... read more

SGLT-2 Inhibitors Tied to Less Death, HF, MI, Stroke: CVD REAL 2

CVD REAL 2 aimed to examine the risk for all-cause death, HF hospitalization, MI, and stroke in patients initiated on an SGLT-2 inhibitor vs another glucose ... "You did not see me show any HbA1c data ... read more

Newer type 2 diabetes drugs show heart protective quality: study

The drugs, known as SGLT-2 inhibitors ... diabetes. (Representational Image) A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us